The first systematic review of palliative care symptoms in rapidly progressive prion disease has concluded that the published quantitative literature records what clinicians noticed while making a diagnosis, and almost nothing about how patients themselves fared. The review, by Rachel T. Williams and colleagues at the MRC Prion Unit at UCL, the National Prion Clinic and the Marie Curie Palliative Care Research Department, was published in BMC Palliative Care on 27 April 2026 (volume 25, article 169). Following PRISMA guidance and registered with PROSPERO (CRD42020194294), the team searched five databases to December 2023, screened 8,503 unique citations and included 30 papers describing 4,434 participants with sporadic, iatrogenic or variant Creutzfeldt-Jakob disease. Inherited prion disease was excluded because its course and care needs differ. Across those papers the reviewers counted 109 distinct symptoms, reported 374 times in total. Motor problems dominated: myoclonus was the single most prevalent symptom in its category at 37.9 per cent (25 of 66), with ataxia at 31.8 per cent (21 of 66). Evidence on social and spiritual symptoms, on quality of life, and on how symptoms change over time was, in the authors' words, limited, because most of the source studies were designed to improve early diagnosis.

For families, the practical point is where the ranking of hardest symptoms actually comes from. The reviewers set their tally against Liz Ford and colleagues' 2019 study in International Psychogeriatrics (volume 31, pages 1181 to 1190), a questionnaire nested in the UK National Prion Monitoring Cohort in which 71 informal carers named their four biggest problems, generating 236 symptoms grouped into ten domains, with 11 carers then interviewed in depth. The six domains carers found most problematic were mobility and coordination; mood and behaviour; personal care and continence; eating and swallowing; communication; and cognition and memory. The new review found that several of these, notably continence, swallowing difficulties and long-term functional decline, appear far less often in the quantitative literature than in carers' accounts.

That gap is the review's central claim, and it has a service consequence. Without formal quality of life assessment in this population, the authors argue, clinicians have little guidance on which interventions relieve distress, and no basis for health economic modelling of services. The gap sits underneath the multidisciplinary UK consensus recommendations for palliative and supportive care in CJD published in Age and Ageing in July 2026 (volume 55, issue 7, afag206), which set out what good practice should look like; the BMC review is the audit of how thin the measured evidence beneath such advice remains. Separately, a retrospective single health system study published in Neurology in September 2025 found that of 172 patients with symptomatic prion disease, 165 (94.8 per cent) had at least one symptom amenable to supportive care, while 113 (65.7 per cent) accessed palliative care resources.

The review has limits its authors acknowledge. It included only English language, peer reviewed, quantitative studies, so the qualitative literature that carries most of the family testimony was outside its scope by design. Symptoms were grouped using artificial intelligence assisted semantic clustering before a palliative care framework was applied, and methodological quality was appraised with the Hawker tool. Percentages describe how often a symptom was reported within a category across papers, not how many patients experienced it.